Single-step affinity purification of enzyme biotherapeutics: a platform methodology for accelerated process development.
Downstream sample purification for quality attribute analysis is a significant bottleneck in process development for non-antibody biologics. Multi-step chromatography process train purifications are typically required prior to many critical analytical tests. This prerequisite leads to limited throughput, long lead times to obtain purified product, and significant resource requirements. In this work, immunoaffinity purification technology has been leveraged to achieve single-step affinity purification of two different enzyme biotherapeutics (Fabrazyme® [agalsidase beta] and Enzyme 2) with polyclonal and monoclonal antibodies, respectively, as ligands. Target molecules were rapidly isolated from cell culture harvest in sufficient purity to enable analysis of critical quality attributes (CQAs). Most importantly, this is the first study that demonstrates the application of predictive analytics techniques to predict critical quality attributes of a commercial biologic. The data obtained using the affinity columns were used to generate appropriate models to predict quality attributes that would be obtained after traditional multi-step purification trains. These models empower process development decision-making with drug substance-equivalent product quality information without generation of actual drug substance. Optimization was performed to ensure maximum target recovery and minimal target protein degradation. The methodologies developed for Fabrazyme were successfully reapplied for Enzyme 2, indicating platform opportunities. The impact of the technology is significant, including reductions in time and personnel requirements, rapid product purification, and substantially increased throughput. Applications are discussed, including upstream and downstream process development support to achieve the principles of Quality by Design (QbD) as well as integration with bioprocesses as a process analytical technology (PAT).
Late Stage Process Development, Genzyme - A Sanofi Company, 45 New York Avenue, Framingham, MA, 01701.
Kevin P
KP
Brower
Venkat K
VK
Ryakala
Ryan
R
Bird
Rahul
R
Godawat
Frank J
FJ
Riske
Konstantin
K
Konstantinov
Veena
V
Warikoo
Jean
J
Gamble
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000302:isolation & purification*; D018929:Cell Culture Techniques; D002846:Chromatography, Affinity / Q000379:methods*; D006801:Humans; D007527:Isoenzymes / Q000737:chemistry* / Q000378:metabolism; D011506:Proteins / Q000737:chemistry / Q000302:isolation & purification*; D059748:Proteolysis; D000519:alpha-Galactosidase / Q000737:chemistry* / Q000378:metabolism
D000911:Antibodies, Monoclonal; D007527:Isoenzymes; D011506:Proteins; D000519:alpha-Galactosidase; C459420:agalsidase beta
affinity chromatography; immunoaffinity; predictive analytics; process development